LONG TERM COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE COMPARED TO DOXORUBICIN PLUS CYCLOPHOSPHAMIDE AS ADJUVANT TREATMENT FOR WOMEN WITH OPERABLE BREAST CANCER

被引：0
|
作者：
Jackson, D. [1 ]
Lee, J. M. [2 ]
Adams, J. [1 ]
Gordois, A. [1 ]
机构：
[1] IMS Hlth, St Leonards, NSW, Australia
[2] Sanofi Aventis Australia Pty Ltd, Macquarie Pk, NSW, Australia
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74342-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A274 / A274
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE VERSUS DOXORUBICIN PLUS CYCLOPHOSPHAMIDE IN THE ADJUVANT TREATMENT OF OPERABLE BREAST CANCER
    Jones, S.
    Chen, L.
    Tangirala, M.
    Asmar, L.
    Airia, P.
    Thompson, M. F.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A45 - A45
  • [2] Long-term survival benefits of docetaxel plus cyclophosphamide compared to doxorubicin plus cyclophosphamide in the adjuvant treatment of operable breast cancer
    Thompson, M.
    Seal, B.
    Tangirala, M.
    Asmar, L.
    Jones, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide
    Peng Liubao
    Wan Xiaomin
    Tan Chongqing
    Karnon, Jon
    Chen Gannong
    Li Jianhe
    Cui Wei
    Luo Xia
    Cao Junhua
    [J]. PHARMACOECONOMICS, 2009, 27 (10) : 873 - 886
  • [4] Adjuvant docetaxel plus doxorubicin and cyclophosphamide increases survival compared with fluorouracil plus doxorubicin and cyclophosphamide in women with operable node-positive breast cancer
    Roy, V
    Perez, EA
    [J]. CANCER TREATMENT REVIEWS, 2006, 32 (01) : 55 - 58
  • [5] Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese PerspectiveDoxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide
    Peng Liubao
    Wan Xiaomin
    Tan Chongqing
    Jon Karnon
    Chen Gannong
    Li Jianhe
    Cui Wei
    Luo Xia
    Cao Junhua
    [J]. PharmacoEconomics, 2009, 27 : 873 - 886
  • [6] Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer
    Jones, Stephen E.
    Savin, Michael A.
    Holmes, Frankie Ann
    O'Shaughnessy, Joyce A.
    Blum, Joanne L.
    Vukelja, Svetislava
    McIntyre, Kristi J.
    Pippen, John E.
    Bordelon, James H.
    Kirby, Robert
    Sandbach, John
    Hyman, William J.
    Khandelwal, Pankaj
    Negron, Angel G.
    Richards, Donald A.
    Anthony, Stephen P.
    Mennel, Robert G.
    Boehm, Kristi A.
    Meyer, Walter G.
    Asmar, Lina
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) : 5381 - 5387
  • [7] Docetaxel plus cyclophosphamide is cost-effective compared to doxorubicin plus cyclophosphamide, based on an economic analysis of US oncology trial 9735: additional rationale to avoid anthracyclines in the adjuvant treatment of operable breast cancer?
    Verma, S.
    Mittmann, N.
    Bernard, L.
    Thompson, M.
    Chan, B.
    Asmar, L.
    Jones, S.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 378S - 378S
  • [8] Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer
    Adeel, Muhammad
    Asif, Muhammad
    Faisal, Muhammad Naeem
    Chaudary, Muhammad Hasanain
    Malik, Muhammad Sheraz
    Khalid, Muhammad
    [J]. CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 727 - 739
  • [9] Cost-Effectiveness of Docetaxel-Cyclophosphamide Versus Doxorubicin-Cyclophosphamide for Breast Cancer
    Thompson, Melissa F.
    Chen, Lei
    Tangirala, Muralikrishna
    Asmar, Lina
    Jones, Stephen E.
    [J]. AMERICAN JOURNAL OF PHARMACY BENEFITS, 2011, 3 (05) : 276 - +
  • [10] Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer (vol 24, pg 5381, 2006)
    Jones
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1819 - 1819
12345